Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;50(11):1359-1366.
doi: 10.1111/imj.14640.

Real-world direct oral anticoagulant experience in atrial fibrillation: falls risk and low dose anticoagulation are predictive of both bleeding and stroke risk

Rowena Brook  1 , Oranut Aswapanyawongse  1 , Mark Tacey  2   3 , Tanun Kitipornchai  2 , Prahlad Ho  1   4 , Hui Y Lim  1   4
Affiliations

Real-world direct oral anticoagulant experience in atrial fibrillation: falls risk and low dose anticoagulation are predictive of both bleeding and stroke risk

Rowena Brook et al. Intern Med J. 2020 Nov.

Abstract

Background: Clinical trials have demonstrated that direct oral anticoagulants (DOAC) are non-inferior to vitamin K antagonist for stroke prevention in non-valvular atrial fibrillation (AF) with comparable safety outcomes; however, real-world Australian data are limited.

Aims: To evaluate local real-world DOAC use focussing on safety, particularly in high-risk patients.

Methods: A retrospective evaluation of 658 patients commenced or continued on DOAC between September 2013 and September 2016 for non-valvular AF at Northern Hospital, a tertiary hospital in Victoria, Australia was performed.

Results: Factor Xa inhibitors were more commonly prescribed than direct thrombin inhibitors (83.3 vs 16.7%) for AF management. The median patient age was 75 years. The rate of clinically significant bleeding on anticoagulation was 3.13 per 100 person-years (including four deaths) with risk factors including history of bleeding (hazard ratio (HR) 3.52, 95% confidence interval (CI) 1.22-10.17), concurrent antiplatelet therapy (HR 2.62, 95% CI: 1.11-6.20) and high falls risk (HR 2.76, 95% CI: 1.26-6.08). Patients on low-dose DOAC had significantly higher bleeding risk compared with those on full dose (5.05 vs 1.82 per 100 person-years). The rate of thrombotic stroke despite anticoagulation was 1.34 per 100 person-years with risk factors including low dose anticoagulation (P = 0.034), high falls risk (P = 0.046) and previous stroke (P = 0.028).

Conclusions: DOAC use in real-world Australian practice is safe and effective, consistent with international data. Low dose anticoagulation and falls risk are associated with increased bleeding and thrombotic risk demonstrating overlapping risk factors. Careful individualised patient risk assessment is still required as low dose anticoagulation is not without risks.

Keywords: anticoagulant; atrial fibrillation; frailty; haemorrhage; thrombosis.

PubMed Disclaimer

References

    1. Ball J, Thompson DR, Ski CF, Carrington MJ, Gerber T, Stewart S. Estimating the current and future prevalence of atrial fibrillation in the Australian adult population. Med J Aust 2015; 202: 32-5.
    1. Pricewaterhouse Coopers for the National Stroke Foundation. The Economic Costs of Atrial Fibrillation in Australia. 2010 [cited 2019 May 26]. Available from URL: https://www.hps.com.au/wp-content/uploads/2016/10/Economic-costs-of-atri...
    1. Pharmaceutical Benefit Scheme: Drug Utilisation Sub-committee, Australian Government, Department of Health. Novel Oral Anticoagulants: Predicted vs actual analysis. 2016 [cited 2019 May 20]. Available from URL: http://www.pbs.gov.au/info/industry/listing/participants/public-release-...
    1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
    1. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.

LinkOut - more resources